CDAK NASDAQ

Codiak BioSciences, Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to pioneering exosome-derived treatments. Its focus spans numerous health challenges, encompassing various cancers (oncology and neuro-oncology), neurological conditions, neuromuscular disorders, and infectious diseases. Leading its pipeline are exoSTING and exoIL-12, both exosome therapeutic candidates engineered to combat a range of solid tumors. Furthermore, the company is progressing exoASO-STAT6, an antisense oligonucleotide specifically targeting the STAT6 transcription factor, as well as exoVACC, a versatile platform for crafting highly precise vaccines. Codiak maintains strategic alliances with several prominent institutions and companies, including Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, the Ragon Institute of MGH, MIT, and Harvard. The enterprise was established in 2015 and is headquartered in Cambridge, Massachusetts.